DK0819129T3 - Pyrazolderivater og fremgangsmåde til deres fremstilling - Google Patents

Pyrazolderivater og fremgangsmåde til deres fremstilling

Info

Publication number: DK0819129T3
Authority: DK; Denmark
Prior art keywords: pct; date oct; preparation; sec; formula
Prior art date: 1995-04-03

Application number

DK96909115T

Other languages

English (en)

Inventor

Peter Traxler

Pascal Furet

Guido Bold

Joerg Frei

Marc Lang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-03

Filing date

1996-03-22

Publication date

2000-10-23

1996-03-22 Application filed by Novartis Ag filed Critical Novartis Ag

2000-10-23 Application granted granted Critical

2000-10-23 Publication of DK0819129T3 publication Critical patent/DK0819129T3/da

Links

150000003217 pyrazoles Chemical class 0.000 title 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK96909115T 1995-04-03 1996-03-22 Pyrazolderivater og fremgangsmåde til deres fremstilling DK0819129T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH93795		1995-04-03
CH42196		1996-02-16
PCT/EP1996/001263 WO1996031510A1 (en)	1995-04-03	1996-03-22	Pyrazole derivatives and processes for the preparation thereof

Publications (1)

Publication Number	Publication Date
DK0819129T3 true DK0819129T3 (da)	2000-10-23

Family

ID=25684532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96909115T DK0819129T3 (da)	1995-04-03	1996-03-22	Pyrazolderivater og fremgangsmåde til deres fremstilling

Country Status (13)

Country	Link
US (1)	US5981533A (da)
EP (1)	EP0819129B1 (da)
JP (1)	JP4249804B2 (da)
AT (1)	ATE195123T1 (da)
AU (1)	AU711592B2 (da)
CA (1)	CA2214086C (da)
DE (1)	DE69609602T2 (da)
DK (1)	DK0819129T3 (da)
ES (1)	ES2150113T3 (da)
GR (1)	GR3034415T3 (da)
NZ (1)	NZ304859A (da)
PT (1)	PT819129E (da)
WO (1)	WO1996031510A1 (da)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (da) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
EP0824525B1 (en) *	1995-04-27	2001-06-13	AstraZeneca AB	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
EP0836605B1 (en) *	1995-07-06	2002-02-06	Novartis AG	Pyrrolopyrimidines and processes for the preparation thereof
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
AU1441497A (en) *	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
WO1997030035A1 (en)	1996-02-13	1997-08-21	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ES2169355T3 (es)	1996-03-05	2002-07-01	Astrazeneca Ab	Derivados de 4-anilinoquinazolina.
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
AU720429B2 (en)	1996-08-23	2000-06-01	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
ID18494A (id) *	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
AU4779897A (en) *	1996-10-02	1998-04-24	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
ES2239779T3 (es) *	1996-10-02	2005-10-01	Novartis Ag	Derivados de pirimidina y procedimientos para la preparacion de los mismos.
CA2272705C (en) *	1996-11-27	2003-03-18	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
CA2304565A1 (en) *	1997-10-06	1999-04-15	Basf Aktiengesellschaft	Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives
CA2304466A1 (en)	1997-10-06	1999-04-15	Basf Aktiengesellschaft	Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
AU3053999A (en)	1998-03-31	1999-10-25	Kyowa Hakko Kogyo Co. Ltd.	Nitrogenous heterocyclic compounds
KR20020088406A (ko) *	1999-09-17	2002-11-27	애보트 게엠베하 운트 콤파니 카게	치료제로서의 피라졸로피리미딘
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
CN100376567C (zh)	1999-11-05	2008-03-26	阿斯特拉曾尼卡有限公司	作为vegf抑制剂的喹唑啉衍生物
ES2309206T3 (es) *	2001-10-02	2008-12-16	Smithkline Beecham Corporation	Compuestos quimicos.
US20050080026A1 (en)	2001-10-29	2005-04-14	Arnd Steuernagel	Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
MXPA05000946A (es) *	2002-07-25	2005-05-16	Pharmacia Italia Spa	Derivados heterociclicos condensados de pirazol como inhibidores de cinasa.
US20040121407A1 (en) *	2002-09-06	2004-06-24	Elixir Pharmaceuticals, Inc.	Regulation of the growth hormone/IGF-1 axis
CA2527496C (en)	2003-05-28	2012-08-14	Francesco Bondavalli	4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof
US7429596B2 (en) *	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
DE10356579A1 (de)	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
JP2008515980A (ja) *	2004-10-12	2008-05-15	デコードジェネティクスイーエイチエフ	閉塞性動脈疾患のためのアリールスルホンアミドぺリ置換二環式化合物
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
US7947676B2 (en)	2004-12-14	2011-05-24	Astrazeneca Ab	Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
CN101277939A (zh) *	2005-09-09	2008-10-01	布里斯托尔-迈尔斯斯奎布公司	无环ikur抑制剂
KR20080107466A (ko)	2006-03-09	2008-12-10	파마코페이아, 인코포레이티드	대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제
EA200870409A1 (ru)	2006-04-04	2009-04-28	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Антагонисты киназы pi3
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2711558C (en)	2008-01-04	2016-12-13	Intellikine, Inc.	Phosphatidyl inositol-3 kinase inhibiting compounds
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
AU2009268611B2 (en)	2008-07-08	2015-04-09	Intellikine, Llc	Kinase inhibitors and methods of use
JP5731978B2 (ja)	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
CA2740885C (en)	2008-10-16	2018-04-03	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010054264A1 (en)	2008-11-07	2010-05-14	Triact Therapeutics, Inc.	Use of catecholic butane derivatives in cancer therapy
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
WO2010099137A2 (en)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the emt status of tumor cells in vivo
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en)	2009-03-18	2012-03-15	Maryland Franklin	Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
EP2427195B1 (en)	2009-05-07	2019-05-01	Intellikine, LLC	Heterocyclic compounds and uses thereof
MY162604A (en)	2009-08-17	2017-06-30	Intellikine Llc	Heterocyclic compounds and uses thereof
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
EP2510110A1 (en)	2009-11-13	2012-10-17	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
AU2012205669B2 (en)	2011-01-10	2015-08-20	Infinity Pharmaceuticals Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
JP6027610B2 (ja)	2011-07-19	2016-11-16	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環式化合物及びその使用
US9056877B2 (en)	2011-07-19	2015-06-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2751093A1 (en)	2011-08-29	2014-07-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2845179A1 (en)	2011-08-31	2013-03-07	Genentech, Inc.	Diagnostic markers
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013055530A1 (en)	2011-09-30	2013-04-18	Genentech, Inc.	Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
KR102229478B1 (ko)	2012-11-01	2021-03-18	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
GB201223308D0 (en)	2012-12-21	2013-02-06	Univ Sunderland	Enzyme inhibitors
EP2961412A4 (en)	2013-02-26	2016-11-09	Triact Therapeutics Inc	CANCER THERAPY
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976085A1 (en)	2013-03-21	2016-01-27	INSERM - Institut National de la Santé et de la Recherche Médicale	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US9381246B2 (en)	2013-09-09	2016-07-05	Triact Therapeutics, Inc.	Cancer therapy
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PE20160685A1 (es)	2013-10-04	2016-07-23	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos
SG10201808053XA (en)	2014-03-19	2018-10-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016004305A2 (en)	2014-07-02	2016-01-07	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3237638B1 (en)	2014-12-24	2020-01-15	F.Hoffmann-La Roche Ag	Therapeutic, diagnostic and prognostic methods for cancer of the bladder
US10160761B2 (en)	2015-09-14	2018-12-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EA201892368A1 (ru) *	2016-04-19	2019-05-31	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа	ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX391135B (es)	2016-06-24	2025-03-21	Infinity Pharmaceuticals Inc	Terapias de combinacion.
CA3048217A1 (en)	2016-12-22	2018-06-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
ES2905676T3 (es)	2017-05-22	2022-04-11	Amgen Inc	Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh)	2017-09-08	2023-01-03	美国安进公司	Kras g12c的抑制剂及其使用方法
MX2020010836A (es)	2018-05-04	2021-01-08	Amgen Inc	Inhibidores de kras g12c y métodos para su uso.
ES2995514T3 (en)	2018-05-04	2025-02-10	Amgen Inc	Kras g12c inhibitors and methods of using the same
EP3790886B1 (en)	2018-05-10	2024-06-26	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
AU2019278998B2 (en)	2018-06-01	2023-11-09	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
CN113194752A (zh)	2018-06-01	2021-07-30	康奈尔大学	Pi3k相关疾病或病症的组合疗法
MX2020012204A (es)	2018-06-11	2021-03-31	Amgen Inc	Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en)	2018-06-12	2020-03-12	Amgen Inc.	Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
CA3115038A1 (en)	2018-10-04	2020-04-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Egfr inhibitors for treating keratodermas
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
CA3117222A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
PE20211475A1 (es)	2018-12-20	2021-08-05	Amgen Inc	Inhibidores de kif18a
MX2021007157A (es)	2018-12-20	2021-08-16	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a.
CA3123227A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Heteroaryl amides useful as kif18a inhibitors
WO2020132651A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Kif18a inhibitors
JP2022522777A (ja)	2019-03-01	2022-04-20	レボリューションメディシンズインコーポレイテッド	二環式ヘテロアリール化合物及びその使用
EP3930845A1 (en)	2019-03-01	2022-01-05	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
CN114144414B (zh)	2019-05-21	2025-11-07	美国安进公司	固态形式
CA3147272A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
US12540129B2 (en)	2019-08-02	2026-02-03	Amgen Inc.	KIF18A inhibitors
WO2021026101A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
CN114302880B (zh)	2019-08-02	2025-07-15	美国安进公司	Kif18a抑制剂
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN114786777A (zh)	2019-11-04	2022-07-22	锐新医药公司	Ras抑制剂
CN114867735A (zh)	2019-11-04	2022-08-05	锐新医药公司	Ras抑制剂
PE20221277A1 (es)	2019-11-04	2022-09-05	Revolution Medicines Inc	Inhibidores de ras
PE20230249A1 (es)	2019-11-08	2023-02-07	Revolution Medicines Inc	Compuestos de heteroarilo biciclicos y usos de estos
TW202132271A (zh)	2019-11-14	2021-09-01	美商安進公司	Ｋｒａｓｇ１２ｃ抑制劑化合物之改善的合成
CA3158188A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (en)	2019-11-27	2022-10-05	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
CA3163703A1 (en)	2020-01-07	2021-07-15	Steve Kelsey	Shp2 inhibitor dosing and methods of treating cancer
KR20230042600A (ko)	2020-06-18	2023-03-28	레볼루션 메디슨즈, 인크.	Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CA3187757A1 (en)	2020-09-03	2022-03-24	Ethan AHLER	Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111B2 (en)	2020-09-15	2025-11-27	Revolution Medicines, Inc.	Indole derivatives as Ras inhibitors in the treatment of cancer
EP4267250A1 (en)	2020-12-22	2023-11-01	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
AR125782A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
CR20230558A (es)	2021-05-05	2024-01-24	Revolution Medicines Inc	Inhibidores de ras para el tratamiento del cáncer
EP4334324A1 (en)	2021-05-05	2024-03-13	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023114954A1 (en)	2021-12-17	2023-06-22	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
IL314883A (en)	2022-03-07	2024-10-01	Amgen Inc	Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
AU2023285116A1 (en)	2022-06-10	2024-12-19	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
EP4601644A1 (en)	2022-10-14	2025-08-20	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en)	2023-04-07	2026-02-11	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024216016A1 (en)	2023-04-14	2024-10-17	Revolution Medicines, Inc.	Crystalline forms of a ras inhibitor
AU2024252105A1 (en)	2023-04-14	2025-10-16	Revolution Medicines, Inc.	Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN121712509A (zh)	2023-05-04	2026-03-20	锐新医药公司	用于ras相关疾病或病症的组合疗法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
IL327306A (en)	2023-10-12	2026-05-01	Revolution Medicines Inc	Macrocyclic RAS inhibitors
WO2025137507A1 (en)	2023-12-22	2025-06-26	Regor Pharmaceuticals, Inc.	Sos1 inhibitors and uses thereof
CN117865965B (zh) *	2024-01-08	2024-06-28	贵州省天然产物研究中心	吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer
WO2026090116A2 (en)	2024-10-21	2026-04-30	Revolution Medicines, Inc.	Ras inhibitors
WO2026090245A1 (en)	2024-10-22	2026-04-30	Revolution Medicines, Inc.	Use of ras inhibitors for treating cancer
US20260108528A1 (en)	2024-10-22	2026-04-23	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102780C (en) *	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0831829B1 (en) *	1995-06-07	2003-08-20	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
ES2239779T3 (es) *	1996-10-02	2005-10-01	Novartis Ag	Derivados de pirimidina y procedimientos para la preparacion de los mismos.
AU4779897A (en) *	1996-10-02	1998-04-24	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
MX219077B (en) *	1996-10-04	2004-02-10	Procter & Gamble	Process for making a detergent composition by non-tower process

1996
- 1996-03-22 JP JP52992996A patent/JP4249804B2/ja not_active Expired - Fee Related
- 1996-03-22 ES ES96909115T patent/ES2150113T3/es not_active Expired - Lifetime
- 1996-03-22 EP EP96909115A patent/EP0819129B1/en not_active Expired - Lifetime
- 1996-03-22 WO PCT/EP1996/001263 patent/WO1996031510A1/en not_active Ceased
- 1996-03-22 AU AU52733/96A patent/AU711592B2/en not_active Ceased
- 1996-03-22 US US08/930,904 patent/US5981533A/en not_active Expired - Lifetime
- 1996-03-22 DE DE69609602T patent/DE69609602T2/de not_active Expired - Lifetime
- 1996-03-22 PT PT96909115T patent/PT819129E/pt unknown
- 1996-03-22 NZ NZ304859A patent/NZ304859A/xx not_active IP Right Cessation
- 1996-03-22 CA CA002214086A patent/CA2214086C/en not_active Expired - Fee Related
- 1996-03-22 DK DK96909115T patent/DK0819129T3/da active
- 1996-03-22 AT AT96909115T patent/ATE195123T1/de active
2000
- 2000-09-15 GR GR20000402103T patent/GR3034415T3/el unknown

Also Published As

Publication number	Publication date
DE69609602D1 (de)	2000-09-07
CA2214086A1 (en)	1996-10-10
ES2150113T3 (es)	2000-11-16
AU711592B2 (en)	1999-10-14
GR3034415T3 (en)	2000-12-29
US5981533A (en)	1999-11-09
EP0819129B1 (en)	2000-08-02
NZ304859A (en)	2000-01-28
AU5273396A (en)	1996-10-23
JPH11502859A (ja)	1999-03-09
PT819129E (pt)	2001-01-31
JP4249804B2 (ja)	2009-04-08
CA2214086C (en)	2008-07-29
ATE195123T1 (de)	2000-08-15
DE69609602T2 (de)	2001-04-12
EP0819129A1 (en)	1998-01-21
WO1996031510A1 (en)	1996-10-10

Publication	Publication Date	Title
GR3034415T3 (en)	2000-12-29	Pyrazole derivatives and processes for the preparation thereof
DK0836605T3 (da)	2002-05-13	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
ATE291022T1 (de)	2005-04-15	Pyrimiderivate und verfahren zu ihrer herstellung
DK0888353T3 (da)	2003-10-27	N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
ATE384062T1 (de)	2008-02-15	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
AP9901435A0 (en)	1999-03-31	Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
BR0014973A (pt)	2002-07-16	Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
MY128370A (en)	2007-01-31	Pyrrolotriazane inhibitors of kinases
DK0520722T3 (da)	1997-06-23	Terapeutiske præparater indeholdende quinazolinderivater
MD1632G2 (ro)	2001-12-31	Compuşi biciclici, metodă de inhibare a receptorulor tirozinkinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitelor şi de tratament al mamiferelor
IT1277392B1 (it)	1997-11-10	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
NO971038L (no)	1997-05-06	Pyrimido£5,4-d\|pyrimidiner, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling av dem
DK611686A (da)	1987-06-22	Pyrazolinderivater, fremgangsmaade til fremstilling deraf og deres anvendelse som middel med insekticid og akaricid virkning
ATE208778T1 (de)	2001-11-15	Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
NO984081L (no)	1998-09-04	Pyrimido[5,4-d]pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremtilling derav
NO993027D0 (no)	1999-06-18	Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
DK165447C (da)	1993-04-13	2-pyrimidinyl-1-piperazin-derivater, fremgangsmaader til deres fremstilling og laegemidler indeholdende dem
NO20003397D0 (no)	2000-06-29	3 '-empiriske K-252A-derivater
DK358586A (da)	1987-01-30	Fremgangsmaade til fremstilling af 2-acyl-3,4-dialkoxyaniliner